Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks
intervals in combination with trastuzumab as 1st and 2nd line treatment of women with
metastatic HER2 positive breast cancer.
Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic
breast cancer, and capsules are generally better tolerated.